This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cutts, S. M. Articles by Phillips, D. R. Search for Related Content PubMed PubMed Citation Articles by Cutts, S. M. Articles by Phillips, D. R.

Molecular Basis for the Synergistic Interaction of Adriamycin with the Formaldehyde-releasing Prodrug Pivaloyloxymethyl Butyrate (AN-9)¹

Department of Biochemistry, La Trobe University, Victoria 3086, Australia [S. M. C., D. R. P.]; Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva 49100, Israel [A. R.]; and Chemistry Department, Bar Ilan University, Ramat Gan 52900, Israel [A. N., I. H.]

The interaction of Adriamycin and pivaloyloxymethyl butyrate (AN-9) was investigated in IMR-32 neuroblastoma and MCF-7 breast adenocarcinoma cells. Adriamycin is a widely used anticancer drug, whereas AN-9 is an anticancer agent presently undergoing Phase II clinical trials. The anticancer activity of AN-9 has been attributed to its ability to act as a butyric acid prodrug, although it also releases formaldehyde and pivalic acid. Adriamycin and AN-9 in combination display synergy when exposed simultaneously to cells or when AN-9 treatment is up to 18 h after Adriamycin administration. However, the reverse order of addition results in antagonism. These interactions have been established using cell viability assays and classical isobologram analysis. To understand the molecular basis of this synergy, the relative levels of Adriamycin-DNA adducts were determined using various treatment combinations. Levels of Adriamycin-DNA adducts were enhanced when treatment combinations known to be synergistic were used and were diminished using those treatments known to be antagonistic. The relative timing of the addition of Adriamycin and AN-9 was critical, with a 20-fold enhancement of Adriamycin-DNA adducts occurring when AN-9 was administered 2 h after the exposure of cells to Adriamycin. The enhanced levels of these adducts and the accompanying decreased cell viability were directly related to the esterase-dependent release of formaldehyde from AN-9, providing evidence for the formaldehyde-mediated activation of Adriamycin.

This article has been cited by other articles:

				K. E. Coldwell, S. M. Cutts, T. J. Ognibene, P. T. Henderson, and D. R. Phillips Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations Nucleic Acids Res., September 1, 2008; 36(16): e100 - e100. [Abstract] [Full Text] [PDF]

				B. J. Evison, F. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts Formaldehyde-Activated Pixantrone Is a Monofunctional DNA Alkylator That Binds Selectively to CpG and CpA Doublets Mol. Pharmacol., July 1, 2008; 74(1): 184 - 194. [Abstract] [Full Text] [PDF]

				B. J. Evison, O. C. Mansour, E. Menta, D. R. Phillips, and S. M. Cutts Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent Nucleic Acids Res., June 28, 2007; 35(11): 3581 - 3589. [Abstract] [Full Text] [PDF]

				M. Entin-Meer, X. Yang, S. R. VandenBerg, K. R. Lamborn, A. Nudelman, A. Rephaeli, and D. A. Haas-Kogan In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas Neuro-oncol, April 1, 2007; 9(2): 82 - 88. [Abstract] [Full Text] [PDF]

				S. M. Cutts, L. P. Swift, V. Pillay, R. A. Forrest, A. Nudelman, A. Rephaeli, and D. R. Phillips Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate Mol. Cancer Ther., April 1, 2007; 6(4): 1450 - 1459. [Abstract] [Full Text] [PDF]

				L. P. Swift, A. Rephaeli, A. Nudelman, D. R. Phillips, and S. M. Cutts Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II-Mediated Form of Cell Death. Cancer Res., May 1, 2006; 66(9): 4863 - 4871. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				B. S. Parker, T. Buley, B. J. Evison, S. M. Cutts, G. M. Neumann, M. N. Iskander, and D. R. Phillips A Molecular Understanding of Mitoxantrone-DNA Adduct Formation: EFFECT OF CYTOSINE METHYLATION AND FLANKING SEQUENCES J. Biol. Chem., April 30, 2004; 279(18): 18814 - 18823. [Abstract] [Full Text] [PDF]

				S. M. Cutts, L. P. Swift, A. Rephaeli, A. Nudelman, and D. R. Phillips Sequence Specificity of Adriamycin-DNA Adducts in Human Tumor Cells Mol. Cancer Ther., July 1, 2003; 2(7): 661 - 670. [Abstract] [Full Text] [PDF]

				A. Batova, L.-e. Shao, M. B. Diccianni, A. L.Y. T. Tanaka, A. Rephaeli, A. Nudelman, and J. Yu The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines Blood, October 16, 2002; 100(9): 3319 - 3324. [Abstract] [Full Text] [PDF]

				L. P. Swift, S. M. Cutts, A. Rephaeli, A. Nudelman, and D. R. Phillips Activation of Adriamycin by the pH-dependent Formaldehyde-releasing Prodrug Hexamethylenetetramine Mol. Cancer Ther., February 1, 2002; 2(2): 189 - 198. [Abstract] [Full Text] [PDF]